UNSPSC 51262504: Betanidine sulfate

This classification denotes an antihypertensive agent and adrenergic antagonist with the molecular formula 2C10H15N3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4THI5N7O2, chemically known as 2-benzyl-1,3-dimethylguanidine but more generally known as betanidine sulfate, which bears US NIH Compound Identifier 2368. European Medicines Agency schedules Betanidine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00787MIG.

Most nations, for tariff and trade purposes, schedule betanidine sulfate under HS 29252900. SMILES: CNC(=NCC1CCCCC1)NC.CNC(=NCC1CCCCC1)NC.OS(=O)(=O)O.

UNSPSC 51262504 Betanidine sulfate is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health-system supplies, though the recent opportunities show a significant mismatch between the code's nominal scope and the work actually being solicited. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually—neither of which is betanidine sulfate—through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting strategies between state agencies and pharmaceutical manufacturers, again unrelated to betanidine sulfate specifically. Both solicitations signal issuing bodies' interest in pharmaceutical procurement and pharmacy benefit management, but neither targets the specific chemical compound the code nominally describes.

The code shows little relevant recent activity aligned to its stated scope. The Seminole County opportunity targets emergency-response pharmaceuticals (Naloxone) and drug deactivation systems, while the Texas HHS RFI focuses on pharmacy benefit program logistics and direct-to-manufacturer contracting models. Neither procurement represents demand for betanidine sulfate itself. Geographic activity in the recent sample spans Florida and Texas, but the mismatch between code assignment and actual procurement scope suggests either inconsistent coding practices in these jurisdictions' procurement systems or that the code has been applied in error to broader pharmaceutical and pharmacy-benefit opportunities that do not align with the specific commodity it names. Firms tracking this code should verify with issuing agencies whether future activity will target betanidine sulfate directly or whether the code continues to serve as a catch-all for wider pharmaceutical and health-system supply categories.